Minaris Advanced Therapies Expands Operations with a High-Tech GMP Factory, Bolstering Global Cell and Gene Therapy Expansion
Minaris Advanced Therapies, a portfolio company of Altaris, has opened a new Good Manufacturing Practice (GMP) manufacturing facility in Taufkirchen, Munich, Germany. This state-of-the-art facility strengthens Minaris' global manufacturing network and reinforces its position as a trusted partner in advancing cutting-edge therapies.
The new facility, strategically located minutes from Munich International Airport, boasts six Grade B/A cleanrooms for aseptic manufacturing, a Grade C cleanroom for bioreactors and closed systems, and 2,411 ft² of expansion space. It includes dedicated process development and quality control laboratories, cryopreservation and storage facilities, and independently controlled HVAC systems enabling parallel production.
The consolidation of process and analytical development, as well as legacy manufacturing operations into one location, enhances operational efficiency and flexibility in cell and gene therapy production. The facility's proximity to the airport provides significant logistical advantages for clients across Europe and beyond, supporting efficient supply chain and distribution operations.
Iain Baird, Chairman of the Board, Minaris Advanced Therapies, said that the facility embodies their shared vision for the future of cell and gene therapy manufacturing - scalable, flexible, and globally integrated. Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies, stated that the opening of this facility marks an important milestone in their mission to accelerate the development and manufacturing of transformative cell and gene therapies globally.
Minaris Advanced Therapies, a global contract development and manufacturing organization and contract testing provider, has over 650,000 square feet of infrastructure across the United States, Europe, and Asia. The company has manufactured and released over 7,500 GMP batches and focuses on cell and gene therapies.
Altaris, an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, has invested in over 50 companies across various healthcare sub-sectors. For more information about Altaris, visit www.altariscap.com.
This facility, designed to support technology transfer of commercial advanced therapies into Europe, strengthens Minaris' European footprint and ability to accelerate development and commercialization of advanced therapies. It underscores the company’s decade-long expertise in clinical and commercial manufacturing of advanced therapies.
In summary, the key features and strategic advantages of the new Minaris Advanced Therapies GMP manufacturing facility in Munich, Germany, include:
- Multiple cleanrooms with independently controlled HVAC for parallel aseptic production
- Dedicated labs for process development and quality control
- Cryopreservation and storage infrastructure
- Close proximity to Munich International Airport for logistics
- Consolidation of development and manufacturing functions
- Enhancement of scalable and flexible cell and gene therapy manufacturing capabilities
- Strengthening Minaris’ presence and client support in Europe.
[1] Minaris Advanced Therapies Press Release, 2021. [2] Altaris Press Release, 2021. [3] BioPharma-Reporter, 2021.
In alliance with Minaris' vision for the forefront of cell and gene therapy manufacturing, the new facility in Munich, Germany boasts enhanced capabilities for scalable, flexible, and globally integrated production. Equipped with multiple cleanrooms, dedicated labs, and cryopreservation facilities, it positions Minaris as a key player in the medical-conditions sector, offering health-and-wellness solutions through cutting-edge therapies-and-treatments and technology.
